Go back

Drug regulator asks for input on personalised medicines

The European Medicines Agency has launched a consultation on the lifecycle of personalised medicines and companion diagnostics.

The consultation will feed into the preparation of an EU guideline on the challenges of developing personalised medicines, the EMA said in a statement on 28 July.

Personalised medicines are treatments whose use is targeted based on a patient’s individual characteristics and genetic makeup. They rely on the use of a companion diagnostic that helps identify patients who are most likely to benefit from a specific treatment.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.